This post is presented by our media partner Psychedelic News Wire
View the original article here.
Terran Biosciences, a drug developer based in New York, announced recently that it had obtained patent approval for its psychedelic drugs from the U.S. Patent and Trademark Office. The drugs, which have been designed to treat neurological and psychiatric disorders, are based on psilocybin, namely psilocybin edisylate and psilocybin HCI.
Terran Biosciences describes the drugs as the world’s first new polymorphs and salts of psilocybin, noting that the patents will include techniques for treating the aforementioned disorders.
Dr. Sam Clark, Terran CEO and founder, stated that the company was approaching its goal of providing patients with accessible and affordable psilocybin treatment options. Now, the company is focused on acquiring approval from the FDA for its psilocybin variations. It hopes to have the drugs on the market within five years after said authorization has been obtained.
Currently, the company supplies researchers with psychedelics for their studies and clinical trials.
In addition, the company also obtained approval for what it terms orally active prodrugs of 5-MeO-DMT and DMT. DMT, or N,N-dimethylltryptamine, is a psychedelic and hallucinogenic that occurs naturally in many animals and plants. When ingested, this drug is known to produce intense but brief psychedelic effects.
5-MeO-DMT is a psychedelic classified under tryptamines. This compound can be found in the glands of the Sonoran desert toad or Colorado river toad. Similar to other tryptamines, the compound is used as an entheogen in South America. These psychedelics are generally injected or smoked, or they need a monoamine oxidase inhibitor to be activated orally. Terran has found a way to eliminate this requirement, however. The drugs are currently being tested in clinical trials, with the company noting that it is focused on acquiring FDA approval for these drugs as well.
In other news, the patent office also offered Terran Biosciences a notice of allowance for its ibogaine derivative. Ibogaine is a psychoactive substance found in plants in the Apocynaceae family, such as the Tabernanthe iboga shrub. This shrub is mainly found in central Africa. Ibogaine is known to be an effective treatment for substance-use disorder.
Currently, Terran Biosciences has one of the largest drug-development programs in the psychedelic industry. It is conducting experiments with varieties of psychedelics such as LSD, MDMA and 2CB for the treatment of a range of conditions.
This news from Terran Biosciences comes as psychedelic treatments continue to gain mainstream acceptance in the United States. Legislators from the House and Senate agreed to direct funding toward psychedelic research in a recently approved defense bill.
Many other companies, such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), are also focused on advancing the psychedelic medicine field, and we could soon see a flurry of new drug applications and patents being filed by these startups in the nascent industry.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
